BRAF and melanoma: More recently, encorafenib was approved in 2019 in combination with binimetinib for patients with unresectable or metastatic BRAF V600 mutation–positive melanoma and in combination with cetuximab for patients with metastatic colorectal cancer with BRAF V600E mutations (192).